Welcome to MS Views and News blog

MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.

Categories

Latest Blog Posts

May 1, 2020

Life in the Time of COVID-19 – from New Mobility Magazine (Life beyond wheels)

  • #COVID-19
    /
  • Additional MS resource sites
    /
  • Healthcare Perspectives
    /
  • Misc. MS Related
    /
A trailblazing nurse wheels onto the front lines in New York City; an expectant mother with quadriplegia prepares for the…
#COVID-19

May 1, 2020

Ofatumumab (anti-CD20) Displays Superiority to Teriflunomide in Relapsing MS

  • MS Research Study and Reports
    /
Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression…
MS Research Study and Reports

May 1, 2020

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and…
MS Drug Therapies

May 1, 2020

The COVID-19 pandemic and the use of MS disease-modifying therapies

  • #COVID-19
    /
  • MS Drug Therapies
    /
Maria was distraught after reading about the ‘potential’ epidemic, yet to happen, and the horror stories on Facebook needing reassurance…
#COVID-19

April 30, 2020

What Is COVID-19 Doing to the Brain?

  • #COVID-19
    /
  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
Evidence is emerging that the virus that causes COVID-19 can invade the central nervous system.  By Trevis Gleason For Life With…
#COVID-19

April 29, 2020

New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis

  • MS Research Study and Reports
    /
  • Multiple Sclerosis
    /
  • Ocrevus
    /
Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a…
MS Research Study and Reports

April 28, 2020

What We Know About Multiple Sclerosis and COVID-19 – a Video by Stephen Krieger, MD

  • #COVID-19
    /
  • Multiple Sclerosis
    /
Stephen Krieger, MD DISCLOSURES  April 17, 2020 Click HERE to Subscribe for the MS Beacon Newsletter ………………………………………………………………………… This article is posted and…
#COVID-19

April 28, 2020

COVID-19 and MS – Global Data Sharing Initiative

  • #COVID-19
    /
  • Multiple Sclerosis
    /
https://msdataalliance.com/covid-19/covid-19-and-ms-global-data-sharing-initiative/#lnk01 #DataSavesLives – #MSCOVID19 As the COVID-19 pandemic unfolds across the globe, the demand for data on the impact of…
#COVID-19

April 27, 2020

OCREVUS® (ocrelizumab) Pregnancy Registry

  • MS Drug Therapies
    /
  • Multiple Sclerosis
    /
OCREVUS® (ocrelizumab) Pregnancy Registry https://www.ocrevuspregnancyregistry.com/ Do you have multiple sclerosis (MS) and are you pregnant? Then you may be able…
MS Drug Therapies

April 26, 2020

Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show

  • MS Drug Therapies
    /
APRIL 22, 2020 –  BY MARISA WEXLER, MS Click HERE to Subscribe for the MS Beacon Newsletter People with secondary progressive…
MS Drug Therapies

Categories

Latest Blog Posts